This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Oct. 21, 2013 /PRNewswire/ -- Biotechnology has been one of the strongest performing industries through the first three quarters of 2013, returning 58.3% versus 18.6% for the S&P 500™ index as of
September 30, 2013. On
Wednesday, October 23rd at
11am EDT, S&P Capital IQ will host a webinar to discuss the factors that have been driving the biotech bull market and whether it's set to continue its run in the months to come.
This webinar, part of the S&P Capital IQ "ETF Analyst Hour" series, will be titled "Biotech Bull Market: How Long Can It Last?" and will feature
Steve Silver, Senior Industry Analyst at S&P Capital IQ, providing an overview of the biotech industry, including the factors that have been contributing to its strong recent performance. Silver will be joined by
Todd Rosenbluth, S&P Capital IQ's Director of ETF and Mutual Fund Research, who will share his insights on the pros and cons of biotech-specific ETFs and how much exposure to biotech investors may be able to obtain through more diversified ETFs.
This webinar is the latest in S&P Capital IQ's monthly ETF Analyst Hour series and
one hour of CFP continuing education credit is available to attendees. Interested attendees can register here:
http://bit.ly/18WZTfcAnthony Hohmann, ETF product manager, will moderate the discussion and highlight S&P Capital IQ's ETF holdings-based ranking methodology and model performance to date.
Following the presentation, the ETF research reports for the ETFs discussed will be available to all attendees. The ETF reports are initially published on S&P Capital IQ's
MarketScope Advisor platform.
@spmarketscope and #ETFHour during the webinar for up-to-the-second ETF commentary from S&P Capital IQ equity analysts.
About S&P Capital IQS&P Capital IQ, a business line of McGraw Hill Financial (NYSE: MHFI), is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. Evaluated pricing is prepared by Standard & Poor's Securities Evaluations, Inc., a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities & Exchange Commission. S&P capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information visit
Standard & Poor's Financial Services LLC, its affiliates (together, S&P) or their third-party providers do not guarantee the accuracy, completeness or timeliness of any information, including model, software or application, they provide, and are not responsible for errors and omissions (negligent or otherwise), or for the results obtained from the use of such information. S&P and its third party providers disclaim any and all express or implied warranties.